Literature DB >> 27060989

High prevalence of risk factors in elderly patients using drugs associated with acquired torsades de pointes chronically in Colombia.

Paula Andrea Moreno-Gutiérrez1, Andrés Gaviria-Mendoza1, Mauricio Montoya Cañón1, Jorge Enrique Machado-Alba1.   

Abstract

AIMS: Medication is one of the main causes of long QT syndrome (LQTS) and torsades de pointes (TdP), and the older adult population is at particularly high risk. The aim of the present study was to describe the prescription patterns of drugs with a risk of TdP in the Colombian older adult population.
METHODS: Patients older than 65 years who received medication with a risk of TdP during three consecutive months were selected. The medication was obtained and classified according to the QT Drug List from Crediblemeds.org. The data were analysed using SPSS-22.
RESULTS: A total of 55 932 patients were chronically receiving QT-prolonging drugs; 61.9% (n = 34 ,632) were women and the mean age of the sample was 75.6 years. Drugs with a conditional risk were consumed by 95.2% of patients, 5.3% received drugs with a known risk and 2.9% received drugs with a possible risk. Two or more QT-prolonging drugs were consumed by 10.3% of the patients (n = 5786). Most of the sample (96.8%, n = 54 170) had at least one additional risk factor for LQTS, with a mean of 3.1 ± 0.9 risk factors. Patients receiving QT-prolonging drugs for psychiatric and neurological disease were at a higher risk of major polypharmacy [odds ratio (OR) 3.0; 95% confidence interval (CI) 2.80, 3.22) and of receiving high doses of QT-prolonging drugs (OR 3.8; 95% CI 3.52, 4.05).
CONCLUSIONS: The widespread use of medication that causes TdP and the high prevalence of additional risks in the older adult population raise the need for accurate prediction of risk and constant patient monitoring. Patients taking psychiatric drugs are at a higher risk of TdP.
© 2016 The British Pharmacological Society.

Entities:  

Keywords:  Colombia; aged; drug-related side effects and adverse reactions; long QT syndrome; pharmacovigilance; torsades de pointes

Mesh:

Year:  2016        PMID: 27060989      PMCID: PMC4972167          DOI: 10.1111/bcp.12969

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  36 in total

1.  QTc and psychotropic drugs.

Authors:  F De Ponti; E Poluzzi; N Montanaro; J Ferguson
Journal:  Lancet       Date:  2000-07-01       Impact factor: 79.321

Review 2.  Drug induced QT prolongation and torsades de pointes.

Authors:  Yee Guan Yap; A John Camm
Journal:  Heart       Date:  2003-11       Impact factor: 5.994

Review 3.  Drug-induced prolongation of the QT interval.

Authors:  Dan M Roden
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

4.  Drug-induced proarrhythmia and use of QTc-prolonging agents: clues for clinicians.

Authors:  E Kevin Heist; Jeremy N Ruskin
Journal:  Heart Rhythm       Date:  2005-11       Impact factor: 6.343

Review 5.  What clinicians should know about the QT interval.

Authors:  Sana M Al-Khatib; Nancy M Allen LaPointe; Judith M Kramer; Robert M Califf
Journal:  JAMA       Date:  2003 Apr 23-30       Impact factor: 56.272

Review 6.  Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview.

Authors:  Fabrizio De Ponti; Elisabetta Poluzzi; Andrea Cavalli; Maurizio Recanatini; Nicola Montanaro
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 7.  Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.

Authors:  G K Dresser; J D Spence; D G Bailey
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

8.  Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program.

Authors:  L V Franse; M Pahor; M Di Bari; G W Somes; W C Cushman; W B Applegate
Journal:  Hypertension       Date:  2000-05       Impact factor: 10.190

9.  Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients.

Authors:  Lesley H Curtis; Truls Østbye; Veronica Sendersky; Steve Hutchison; Nancy M Allen LaPointe; Sana M Al-Khatib; Sally Usdin Yasuda; Peter E Dans; Alan Wright; Robert M Califf; Raymond L Woosley; Kevin A Schulman
Journal:  Am J Med       Date:  2003-02-01       Impact factor: 4.965

Review 10.  Gender differences in the prescribing of antipsychotic drugs.

Authors:  Mary V Seeman
Journal:  Am J Psychiatry       Date:  2004-08       Impact factor: 18.112

View more
  9 in total

1.  Prevalence of QT interval prolonging drug-drug interactions (QT-DDIs) in psychiatry wards of tertiary care hospitals in Pakistan: a multicenter cross-sectional study.

Authors:  Qasim Khan; Mohammad Ismail; Iqbal Haider; Fahadullah Khan
Journal:  Int J Clin Pharm       Date:  2017-09-12

2.  Prevalence and Risk Factors of Drug-Associated Corrected QT Prolongation in Elderly Hospitalized Patients: Results of a Retrospective Analysis of Data Obtained Over 6 Months.

Authors:  Ophélie Maison; Blandine de la Gastine; Laurent Dayot; Sylvain Goutelle
Journal:  Drugs Aging       Date:  2017-07       Impact factor: 3.923

Review 3.  Risk assessment tools for QT prolonging pharmacotherapy in older adults: a systematic review.

Authors:  Simone Skullbacka; Marja Airaksinen; Juha Puustinen; Terhi Toivo
Journal:  Eur J Clin Pharmacol       Date:  2022-02-14       Impact factor: 2.953

4.  Prevalence of Torsades de Pointes inducing drugs usage among elderly outpatients in North Jordan Hospitals.

Authors:  Ahmad Al-Azayzih; Sara Gharaibeh; Anan S Jarab; Tareq L Mukattash
Journal:  Saudi Pharm J       Date:  2018-07-29       Impact factor: 4.330

5.  Drug use and torsades de pointes cardiac arrhythmias in Sweden: a nationwide register-based cohort study.

Authors:  Bengt Danielsson; Julius Collin; Anastasia Nyman; Annica Bergendal; Natalia Borg; Maria State; Lennart Bergfeldt; Johan Fastbom
Journal:  BMJ Open       Date:  2020-03-12       Impact factor: 2.692

6.  Identification of Risk of QT Prolongation by Pharmacists When Conducting Medication Reviews in Residential Aged Care Settings: A Missed Opportunity?

Authors:  Louise Christensen; J Rick Turner; Gregory M Peterson; Mark Naunton; Jackson Thomas; Kwang Choon Yee; Sam Kosari
Journal:  J Clin Med       Date:  2019-11-04       Impact factor: 4.241

7.  Top 20 drug - drug interactions, polypharmacy and analysis of the nature of risk factors due to QT interval prolonging drug use in elderly psychiatry outpatients.

Authors:  Biswadeep Das; Saravana Kumar Ramasubbu; Barun Kumar; Vikram Singh Rawat
Journal:  J Family Med Prim Care       Date:  2020-12-31

8.  Leading 20 drug-drug interactions, polypharmacy, and analysis of the nature of risk factors due to QT interval prolonging drug use and potentially inappropriate psychotropic use in elderly psychiatry outpatients.

Authors:  Biswadeep Das; Saravana Kumar Ramasubbu; Akash Agnihotri; Barun Kumar; Vikram Singh Rawat
Journal:  Ther Adv Cardiovasc Dis       Date:  2021 Jan-Dec

9.  Use of Drugs Associated with QT Interval Prolongation at the Hospital Level during the COVID-19 Pandemic in Colombia.

Authors:  Andrés Gaviria-Mendoza; Manuel Enrique Machado-Duque; Luis Fernando Valladales-Restrepo; Carlos Fernando Tovar-Yepes; Jorge Enrique Machado-Alba
Journal:  Int J Vasc Med       Date:  2022-09-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.